Average Weight Loss in the Orforglipron phase 3 ATTAIN-1 Trial Across the 72-week study period, participants: Lost up to 15% of their body weight at the highest dose At 36 mg: 54.6% lost 10%, 36.0% lost 15%, 18.4% lost 20% body weight (all higher than placebo)
Watch Practice Resources Tools and resources to support your practice Access Now Implement new pharmacy services Designed to support practice expansion, the Practice Implementation Center offers resources to help pharmacy personnel plan, develop, and implement new pharmacy services
These use either gel packs that are replaced daily or battery-powered active cooling systems that maintain precise temperatures
10.1016/j.autneu.2024.103198 287 LiuX.LiY.GuM.XuT.WangC.ChangP
These may indicate a need for treatment adjustment or evaluation of underlying conditions
A licensed provider determines whether compounded tirzepatide is appropriate for you